Hoth Therapeutics (NASDAQ:HOTH) Earns “Buy” Rating from D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $5.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 496.02% from the company’s previous close.

A number of other research firms have also commented on HOTH. Wall Street Zen raised Hoth Therapeutics to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Hoth Therapeutics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.00.

Hoth Therapeutics Trading Down 6.7%

NASDAQ HOTH opened at $0.84 on Wednesday. Hoth Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.12. The stock’s fifty day moving average price is $0.98 and its 200-day moving average price is $1.21. The stock has a market cap of $13.01 million, a P/E ratio of -0.79 and a beta of 0.50.

Institutional Investors Weigh In On Hoth Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Lido Advisors LLC bought a new position in shares of Hoth Therapeutics during the 3rd quarter valued at $32,000. Kestra Private Wealth Services LLC bought a new stake in shares of Hoth Therapeutics in the third quarter worth $51,000. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics in the third quarter worth $184,000. Geode Capital Management LLC increased its position in Hoth Therapeutics by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Hoth Therapeutics during the third quarter valued at $232,000. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.